Zacks Research Analysts Raise Earnings Estimates for Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) – Analysts at Zacks Research increased their Q1 2025 earnings per share estimates for Catalyst Pharmaceuticals in a note issued to investors on Wednesday, April 24th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceutical company will post earnings of $0.67 per share for the quarter, up from their previous estimate of $0.64. The consensus estimate for Catalyst Pharmaceuticals’ current full-year earnings is $1.81 per share. Zacks Research also issued estimates for Catalyst Pharmaceuticals’ Q2 2025 earnings at $0.69 EPS, Q3 2025 earnings at $0.67 EPS and FY2025 earnings at $2.70 EPS.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last released its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 earnings per share for the quarter, beating analysts’ consensus estimates of $0.45 by $0.04. The firm had revenue of $110.57 million during the quarter, compared to the consensus estimate of $105.78 million. Catalyst Pharmaceuticals had a return on equity of 26.56% and a net margin of 17.93%.

Several other research firms have also commented on CPRX. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, March 21st. Citigroup assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They set a “buy” rating and a $27.00 price objective for the company. Oppenheimer restated an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a research note on Wednesday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $24.00 price target on shares of Catalyst Pharmaceuticals in a research note on Friday, March 1st. Finally, Bank of America started coverage on Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They set a “buy” rating and a $23.00 price objective for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat, Catalyst Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $26.43.

Catalyst Pharmaceuticals Stock Up 1.4 %

CPRX stock opened at $14.89 on Friday. Catalyst Pharmaceuticals has a 52 week low of $11.09 and a 52 week high of $17.76. The business has a 50-day simple moving average of $15.52 and a 200 day simple moving average of $14.61. The company has a market cap of $1.76 billion, a PE ratio of 24.07, a price-to-earnings-growth ratio of 0.83 and a beta of 0.89.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director David S. Tierney sold 25,000 shares of the stock in a transaction dated Monday, April 8th. The stock was sold at an average price of $15.68, for a total value of $392,000.00. Following the completion of the transaction, the director now directly owns 348,874 shares in the company, valued at $5,470,344.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 12.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Parkside Financial Bank & Trust bought a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $31,000. GAMMA Investing LLC increased its holdings in Catalyst Pharmaceuticals by 72.9% in the first quarter. GAMMA Investing LLC now owns 1,942 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 819 shares during the period. Nisa Investment Advisors LLC increased its holdings in Catalyst Pharmaceuticals by 306.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 5,079 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 3,829 shares during the period. Tower Research Capital LLC TRC raised its position in Catalyst Pharmaceuticals by 84.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,184 shares of the biopharmaceutical company’s stock worth $104,000 after purchasing an additional 2,833 shares during the last quarter. Finally, Sherbrooke Park Advisers LLC acquired a new position in Catalyst Pharmaceuticals during the 3rd quarter worth about $123,000. Institutional investors and hedge funds own 79.22% of the company’s stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.